How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | GMEDGLOBUS MEDICAL INC | DXCMDEXCOM INC | ZBHZIMMER BIOMET HOLDINGS, INC. | BAXBAXTER INTERNATIONAL INC | Median of the restexcluding GMED |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $81.66▲ 2.98 (3.79%) | $80.26▼ 5.48 (6.39%) | $98.81▲ 3.95 (4.16%) | $25.65▲ 0.95 (3.85%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 10.0/10 | 8.7/10 | 7.0/10 | 5.0/10 | 7.0/10 |
| Market value | $11.23B | $30.88B | $19.67B | $13.12B | |
| Revenue | $2.94B | $4.66B | $8.23B | $11.24B | |
| Profit | $537.9M | $836.3M | $705.1M | -$957.0M | |
| Revenue growthChange in sales versus the prior year. | 16.7% | 15.6% | 7.2% | 5.7% | 7.2% |
| Gross marginShare of sales left after the direct cost of producing them. | 67.4% | 60.1% | 69.7% | 30.1% | 60.1% |
| Operating marginShare of sales left after running the business, before interest and tax. | 16.3% | 19.6% | 13.3% | -2.7% | 13.3% |
| Profit marginProfit kept from each dollar of sales. | 18.3% | 17.9% | 8.6% | -8.5% | 8.6% |
| Free cash flow marginCash left after capital spending, as a share of sales. | 20.0% | 23.1% | 17.9% | 3.0% | 17.9% |
| Return on equityProfit against the owners' stake in the company. | 11.8% | 30.5% | 5.6% | -15.6% | 5.6% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | 10.5% | 38.3% | 4.7% | -1.8% | 4.7% |
| P/E ratioPrice paid per dollar of annual profit. | 20.88x | 36.93x | 27.90x | — | 32.41x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | — | — | 12.13x | 30.60x | 21.37x |
| Price to book | 2.46x | 11.25x | 1.55x | 2.14x | 2.14x |
| Debt to equityTotal liabilities compared with owners' stake. | 0.16x | 1.31x | 0.82x | 2.28x | 1.31x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 8/8 | 7/8 | 5/9 | 6/9 | 6.0 |
| Bankruptcy riskAltman Z-Score zone. | safe | safe | grey | grey |
How GMED compares with the others
- GMED's operating margin of 16.3% is higher than the median of the other companies selected (13.3%).
- Its revenue grew faster than the median of the other companies selected: 16.7% against 7.2%.
- It trades at a lower P/E than the median of the other companies selected: 20.9x against 32.4x.
- Its liabilities are lower relative to equity than the median of the other companies selected: 0.2x against 1.3x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.